U.S. top court denies Teva stay in Copaxone patent fight

WASHINGTON, April 18 (Reuters) - U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd that would have prevented a lower court ruling from going into effect while the court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.